サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423333

ホルモン補充療法市場レポート：製品別、投与経路別、疾患タイプ別、地域別、2024年～2032年

Hormone Replacement Therapy Market Report by Product, Route of Administration, Type of Disease, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
ホルモン補充療法市場レポート：製品別、投与経路別、疾患タイプ別、地域別、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のホルモン補充療法市場規模は2023年に91億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて5.5%の成長率（CAGR）を示し、2032年までに151億米ドルに達すると予測しています。ホルモン障害の有病率の上昇、HRTに対する認識と受容の高まり、高齢者人口の拡大、大幅な技術進歩や送達方法における継続的な革新、政府の支援策や償還政策などが、業界を推進する主な要因の一部です。

ホルモン補充療法（HRT）は、個人のホルモンバランスの乱れに対処するために利用される一種の医療行為です。これは、体内で自然に発生するホルモンを補ったり置き換えたりするために、外因性ホルモンを投与することを含みます。HRTは通常、内分泌専門医や婦人科医などのヘルスケア専門家によって、患者の病歴や症状を十分に評価した上で処方されます。コントロールされた量のホルモンを継続的に投与することで、HRTはホルモンの欠乏や変動に伴う症状を緩和することを目的としています。治療は、最適なホルモンレベルが維持されるように綿密にモニターされるため、全体的な健康が促進され、ホルモンバランスの乱れによる悪影響が軽減される可能性があります。

HRT産業は主に、世界人口の間でホルモンバランスの乱れや関連障害が増加していることが原動力となっています。座りっぱなしのライフスタイル、ストレス、加齢など、さまざまな要因がホルモン変動の一因となっており、治療介入の必要性が生じています。さらに、患者や医療専門家の間で、HRTが効果的な治療オプションであるという認識が高まり、受け入れられていることも、市場拡大の一助となっています。これに加えて、老年人口の拡大がHRT市場の重要な成長促進要因として作用しています。加齢に伴い、ホルモンバランスの乱れが蔓延し、HRTの需要が高まる。これに加えて、経皮パッチや埋め込み型デバイスなど、ホルモン投与方法の技術的進歩が進んでおり、便利で的を絞ったホルモン投与が可能になり、患者のコンプライアンスや全体的な治療成績が向上していることが、市場の成長を強化しています。さらに、患者にとって手頃な価格でHRTを利用できるようにすることを目的とした、政府の支援策や有利な償還政策が、市場に有益な成長機会をもたらしています。

ホルモン補充療法市場の動向と促進要因：

ホルモン不均衡疾患の有病率の増加

更年期障害、甲状腺機能低下症、成長ホルモン欠乏症などのホルモンバランス障害は、世界的にますます一般的になってきています。この増加は、座りがちなライフスタイル、ストレス、環境要因、高齢化など様々な要因に起因しています。その結果、これらの疾患の症状を管理するためのHRTに対する需要が高まっています。これに加え、ヘルスケアプロバイダーは、ホルモンバランスの乱れに対処し、罹患者の生活の質を改善する必要性を認識しています。その結果、HRTの処方と使用が急増しています。これらの治療法は、不足したホルモンを補充したり外因性のもので置き換えたりすることでホルモンバランスを回復させ、症状を緩和し、全体的な健康状態を改善することを目的としています。

老年人口の増加

老年人口の増加は、ヘルスケア産業、特にHRT市場を含む様々な分野における市場成長の重要な促進要因です。高齢者人口が増え続けるにつれ、ホルモンバランスの乱れや、医療介入を必要とする関連疾患の有病率が高まっています。加齢に伴い、身体はホルモンの生産と調節の低下を含む自然な生理的変化を遂げます。女性では更年期障害、男性ではアンドロポーズに関連したものを含め、ホルモンバランスの乱れはより一般的になります。これらのアンバランスは、高齢者の生活の質に大きな影響を与える様々な症状や健康合併症を引き起こす可能性があります。HRTは、不足したホルモンを補充または置換することによってホルモン・バランスを回復させ、それによって症状を緩和し、全体的な幸福感を向上させる解決策を提供します。

ホルモン投与法の大幅な技術進歩

継続的な技術進歩は、HRT分野における市場成長の重要な促進要因です。これらの進歩は、治療の選択肢を改善し、患者の体験を向上させ、HRTの普及を拡大する上で重要な役割を果たしています。技術革新により、経皮パッチ、皮下インプラント、ゲルベース製剤など、HRTの新しい製剤や送達方法が開発され、市場拡大に貢献しています。さらに、ヘルスケア分野における著しい進歩は、HRTにおける個別化医療アプローチの開発を促進しています。遺伝子検査やホルモンレベルのモニタリングといった高度な診断技術を利用することで、ヘルスケアプロバイダーは個々の患者固有のニーズに合わせてHRTレジメンを調整し、最適なホルモンバランスを確保しながら副作用を最小限に抑えることができます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 ホルモン補充療法の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 価格分析
  • 市場内訳：製品別
  • 市場内訳：投与経路別
  • 市場内訳：疾患タイプ別
  • 市場内訳：地域別
  • 市場予測
  • SWOT分析
    • 概要
    • 強み
    • 弱み
    • 機会
    • 脅威
  • バリューチェーン分析
    • 概要
    • 研究開発
    • 原料調達
    • 製造
    • マーケティング
    • 流通
    • 最終用途
  • ポーターのファイブフォース分析
    • 概要
    • 買い手の交渉力
    • 供給企業の交渉力
    • 競合の程度
    • 新規参入業者の脅威
    • 代替品の脅威

第6章 市場内訳：製品別

  • エストロゲン補充療法
    • 市場動向
    • 市場予測
  • ヒト成長ホルモン補充療法
    • 市場動向
    • 市場予測
  • 甲状腺代替療法
    • 市場動向
    • 市場予測
  • 男性ホルモン補充療法
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 非経口
    • 市場動向
    • 市場予測
  • 経皮
    • 市場動向
    • 市場予測

第8章 市場内訳：疾患別

  • 更年期障害
    • 市場動向
    • 市場予測
  • 甲状腺機能低下症
    • 市場動向
    • 市場予測
  • 男性性腺機能低下症
    • 市場動向
    • 市場予測
  • 成長ホルモン欠乏症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア太平洋
    • 市場動向
    • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第10章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Bayer AG
    • Eli Lilly & Company
    • Roche
    • Hisamitsu Pharmaceutical Co. Inc.
    • Merck
    • Mylan NV
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Hormone Replacement Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Hormone Replacement Therapy Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hormone Replacement Therapy Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Hormone Replacement Therapy Market: Breakup by Route of Administration (in %), 2023
  • Figure 5: Global: Hormone Replacement Therapy Market: Breakup by Type of Disease (in %), 2023
  • Figure 6: Global: Hormone Replacement Therapy Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Hormone Replacement Therapy Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Hormone Replacement Therapy Industry: SWOT Analysis
  • Figure 9: Global: Hormone Replacement Therapy Industry: Value Chain Analysis
  • Figure 10: Global: Hormone Replacement Therapy Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Hormone Replacement Therapy (Estrogen) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hormone Replacement Therapy (Estrogen) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hormone Replacement Therapy (Human Growth Hormone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hormone Replacement Therapy (Human Growth Hormone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hormone Replacement Therapy (Thyroid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hormone Replacement Therapy (Thyroid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hormone Replacement Therapy (Testosterone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hormone Replacement Therapy (Testosterone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hormone Replacement Therapy (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hormone Replacement Therapy (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hormone Replacement Therapy (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hormone Replacement Therapy (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hormone Replacement Therapy (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hormone Replacement Therapy (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Hormone Replacement Therapy (Transdermal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Hormone Replacement Therapy (Transdermal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Hormone Replacement Therapy (Menopause) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Hormone Replacement Therapy (Menopause) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Hormone Replacement Therapy (Hypothyroidism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Hormone Replacement Therapy (Hypothyroidism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Hormone Replacement Therapy (Male Hypogonadism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Hormone Replacement Therapy (Male Hypogonadism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Hormone Replacement Therapy (Growth Hormone Deficiency) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Hormone Replacement Therapy (Growth Hormone Deficiency) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Hormone Replacement Therapy (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Hormone Replacement Therapy (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Hormone Replacement Therapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Hormone Replacement Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Europe: Hormone Replacement Therapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Europe: Hormone Replacement Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Asia Pacific: Hormone Replacement Therapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Asia Pacific: Hormone Replacement Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Middle East and Africa: Hormone Replacement Therapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Middle East and Africa: Hormone Replacement Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Latin America: Hormone Replacement Therapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Latin America: Hormone Replacement Therapy Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Hormone Replacement Therapy Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hormone Replacement Therapy Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Hormone Replacement Therapy Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Hormone Replacement Therapy Market Forecast: Breakup by Type of Disease (in Million US$), 2024-2032
  • Table 5: Global: Hormone Replacement Therapy Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hormone Replacement Therapy Market: Competitive Structure
  • Table 7: Global: Hormone Replacement Therapy Market: Key Players
目次
Product Code: SR112024A929

Abstract

The global hormone replacement therapy market size reached US$ 9.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032. The rising prevalence of hormonal disorders, increased awareness and acceptance of HRT, expanding geriatric population, significant technological advancements and ongoing innovations in delivery methods, supportive government initiatives and reimbursement policies are some of the major factors propelling the industry.

Hormone replacement therapy (HRT) is a kind of medical treatment utilized to address hormonal imbalances in individuals. It involves the administration of exogenous hormones to supplement or replace the naturally occurring hormones within the body. HRT is typically prescribed by healthcare professionals, such as endocrinologists or gynecologists, after a thorough evaluation of the patient's medical history and symptoms. By continuously providing a controlled dosage of hormones, HRT aims to alleviate symptoms associated with hormonal deficiencies or fluctuations. The treatment is closely monitored to ensure optimal hormone levels are maintained, thus promoting overall well-being and potentially mitigating the adverse effects of hormonal imbalances.

The HRT industry is primarily driven by the increasing prevalence of hormonal imbalances and related disorders among the global population. Various factors, such as sedentary lifestyles, stress, and aging, contribute to hormonal fluctuations, necessitating the need for therapeutic intervention. Moreover, the escalating awareness and acceptance of HRT as an effective treatment option among patients and healthcare professionals are aiding in market expansion. Besides this, the expanding geriatric population is acting as a significant growth-inducing driver of the HRT market. With age, hormonal imbalances become more prevalent, leading to a higher demand for HRT. In addition to this, ongoing technological advancements in hormone delivery methods, such as transdermal patches and implantable devices, providing convenient and targeted administration of hormones, improving patient compliance and overall treatment outcomes are strengthening the market growth. Furthermore, supportive government initiatives and favorable reimbursement policies aimed to ensure affordable access to HRT for patients are presenting remunerative growth opportunities for the market.

Hormone Replacement Therapy Market Trends/Drivers:

Increasing prevalence of hormonal imbalance disorders

Hormonal imbalance disorders such as menopause, hypothyroidism, and growth hormone deficiency are becoming increasingly common worldwide. This rise can be attributed to various factors such as sedentary lifestyles, stress, environmental factors, and an aging population. As a result, there is a growing demand for HRT to manage the symptoms of these disorders. In addition to this, healthcare providers are recognizing the need to address hormonal imbalances and improve the quality of life for affected individuals. As a result, there has been a surge in the prescription and use of HRT. These therapies aim to restore hormonal balance by supplementing or replacing deficient hormones with exogenous sources, alleviating symptoms, and improving overall health outcomes.

Rising geriatric population

The expanding geriatric population is a significant driver of market growth in various sectors, including the healthcare industry and specifically the HRT market. As the elderly population continues to grow, there is an increased prevalence of hormonal imbalances and related conditions that require medical intervention. With aging, the body undergoes natural physiological changes, including a decline in hormone production and regulation. Hormonal imbalances, including those associated with menopause in women and andropause in men, become more common. These imbalances can lead to a range of symptoms and health complications that significantly impact the quality of life for older individuals. HRT offers a solution to restore hormonal balance by supplementing or replacing deficient hormones, thereby alleviating symptoms and improving overall well-being.

Significant technological advancements in hormone delivery methods

Ongoing technological advancements are a significant driver of market growth in the field of HRT. These advancements play a crucial role in improving treatment options, enhancing patient experience, and expanding the reach of HRT. Technological innovations have led to the development of new formulations and delivery methods for HRT, such as transdermal patches, subcutaneous implants, and gel-based formulations are aiding in market expansion. Furthermore, significant advancements in the healthcare sector have facilitated the development of personalized medicine approaches in HRT. With the help of advanced diagnostic techniques, such as genetic testing and hormone level monitoring, healthcare providers can tailor HRT regimens to individual patients' specific needs, ensuring optimal hormone balance and minimizing side effects.

Hormone Replacement Therapy Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global hormone replacement therapy market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on product, route of administration and type of disease.

Breakup by Product:

Estrogen Replacement Therapy

Human Growth Hormone Replacement Therapy

Thyroid Replacement Therapy

Testosterone Replacement Therapy

Others

Estrogen replacement therapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes estrogen, human growth hormone, testosterone, thyroid replacement therapies, and others. According to the report, estrogen replacement therapy represented the largest segment.

The increasing awareness and understanding of the health risks associated with hormonal deficiencies, particularly in women, represents one of the prime factors impelling the demand for estrogen in women. Estrogen plays a vital role in various physiological processes, including bone health, cardiovascular function, and cognitive function. As women age and experience menopause, estrogen levels decrease, leading to symptoms such as hot flashes, mood swings, and increased risk of osteoporosis and cardiovascular diseases. The recognition of these risks has resulted in a higher demand for ERT as a means to alleviate symptoms and mitigate long-term health complications, creating a favorable outlook for market growth. Moreover, the rising focus on promoting quality of life and well-being among women is acting as another significant growth-inducing factor. ERT can effectively manage menopausal symptoms, enabling women to maintain an active and fulfilling lifestyle.

Breakup by Route of Administration:

Oral

Parenteral

Transdermal

Parenteral holds the largest share in the market

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes oral, parenteral and transdermal. According to the report, parenteral accounted for the largest market share.

The expanding demand for parenteral HRT is propelled by the growing need for precise and controlled hormone administration. Parenteral routes, such as injections and implants, offer direct delivery of hormones into the bloodstream, bypassing the digestive system and ensuring optimal absorption. This method allows for accurate dosing and immediate effects, making it particularly beneficial for patients requiring quick symptom relief or precise hormone regulation. In addition to this, the rising preference for long-acting formulations such as depot injections or subcutaneous implants, which provide a sustained and continuous release of hormones over an extended period, eliminating the need for frequent dosing, is aiding in market expansion. Furthermore, the increasing popularity of parenteral HRT among individuals with gastrointestinal issues or malabsorption problems or patients who may have difficulties with oral hormone medications is positively impacting the market growth.

Breakup by Type of Disease:

Menopause

Hypothyroidism

Male Hypogonadism

Growth Hormone Deficiency

Others

Menopauses dominate the market

The report has provided a detailed breakup and analysis of the market based on the type of disease. This includes menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, and others. According to the report, menopause represented the largest segment.

The expanding global female geriatric population is a significant factor impelling the demand for menopause-related HRT. As women age, they experience a decline in estrogen levels, leading to menopausal symptoms such as hot flashes, night sweats, and mood swings. The aging population is driving the need for effective treatments to alleviate these symptoms and improve the quality of life for menopausal women. Moreover, the growing awareness and understanding of the impact of menopause on women's health are contributing to market growth. In addition to this, the availability of diverse treatment options and formulations, including oral tablets, transdermal patches, gels, and sprays, to cater to individual preferences and needs are strengthening market growth.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America exhibits a clear dominance, accounting for the largest hormone replacement therapy market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

Several factors are currently driving the North American hormone replacement therapy (HRT) market. The region is witnessing a rise in the incidences of hormone imbalance disorders, particularly among the geriatric and neonatal populations, fueling the demand for HRT as a means to address these disorders effectively. Furthermore, there is an increasing need for new treatment options that provide better safety results, which is further propelling the market growth in North America. Patients and healthcare professionals are seeking HRT products that offer improved efficacy and minimize potential side effects, thereby driving the demand for advanced therapeutic options. In addition, the region is experiencing a rise in research and development activities focused on hormone replacement products. These endeavors aim to enhance the quality and efficiency of HRT, leading to the development of innovative formulations and treatment approaches.

Competitive Landscape:

The market is characterized by the presence of several key players. These companies compete based on factors such as product portfolio, research and development capabilities, geographical presence, and marketing strategies. Prominent pharmaceutical companies hold a significant market share and play a crucial role in shaping competitive dynamics. These industry leaders leverage their extensive experience, strong distribution networks, and established brand reputation to maintain their market position. In addition to established players, there is also a presence of emerging and niche players that focus on specific segments or regions within the HRT market. These companies often emphasize innovation and develop novel treatment approaches, targeting unmet needs and offering differentiated solutions.

The market research report has provided a comprehensive analysis of the competitive landscape in the industry. Detailed profiles of all major companies have also been provided. Some of the key players include:

Abbott Laboratories

Bayer AG

Eli Lilly & Company

Roche

Hisamitsu Pharmaceutical Co. Inc.

Merck

Mylan

Novartis

Novo Nordisk

Pfizer

Recent Developments:

In February 2022, Pfizer Inc. and OPKO Health, Inc. announced the marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA.

In August 2020, Bayer, a global leader in women's healthcare, announced the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. KaNDy Therapeutics Ltd. recently finished Phase IIb trials for NT-814, a non-hormonal, once-daily oral medication for treating common menopausal symptoms.

Key Questions Answered in This Report

  • 1. What was the size of the global hormone replacement therapy market in 2023?
  • 2. What is the expected growth rate of the global hormone replacement therapy market during 2024-2032?
  • 3. What are the key factors driving the global hormone replacement therapy market?
  • 4. What has been the impact of COVID-19 on the global hormone replacement therapy market?
  • 5. What is the breakup of the global hormone replacement therapy market based on the product?
  • 6. What is the breakup of the global hormone replacement therapy market based on the route of administration?
  • 7. What is the breakup of the global hormone replacement therapy market based on the type of disease?
  • 8. What are the key regions in the global hormone replacement therapy market?
  • 9. Who are the key players/companies in the global hormone replacement therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormone Replacement Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Product
  • 5.6 Market Breakup by Route of Administration
  • 5.7 Market Breakup by Type of Disease
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast
  • 5.10 SWOT Analysis
    • 5.10.1 Overview
    • 5.10.2 Strengths
    • 5.10.3 Weaknesses
    • 5.10.4 Opportunities
    • 5.10.5 Threats
  • 5.11 Value Chain Analysis
    • 5.11.1 Overview
    • 5.11.2 Research and Development
    • 5.11.3 Raw Material Procurement
    • 5.11.4 Manufacturing
    • 5.11.5 Marketing
    • 5.11.6 Distribution
    • 5.11.7 End-Use
  • 5.12 Porters Five Forces Analysis
    • 5.12.1 Overview
    • 5.12.2 Bargaining Power of Buyers
    • 5.12.3 Bargaining Power of Suppliers
    • 5.12.4 Degree of Competition
    • 5.12.5 Threat of New Entrants
    • 5.12.6 Threat of Substitutes

6 Market Breakup by Product

  • 6.1 Estrogen Replacement Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Human Growth Hormone Replacement Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Thyroid Replacement Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Testosterone Replacement Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Transdermal
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Type of Disease

  • 8.1 Menopause
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hypothyroidism
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Male Hypogonadism
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Growth Hormone Deficiency
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Europe
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Asia Pacific
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Abbott Laboratories
    • 10.3.2 Bayer AG
    • 10.3.3 Eli Lilly & Company
    • 10.3.4 Roche
    • 10.3.5 Hisamitsu Pharmaceutical Co. Inc.
    • 10.3.6 Merck
    • 10.3.7 Mylan NV
    • 10.3.8 Novartis AG
    • 10.3.9 Novo Nordisk A/S
    • 10.3.10 Pfizer Inc.